STANDARD BIOTOOLS INC. LAB

About STANDARD BIOTOOLS INC. (LAB): stock profile, AI score and financials

STANDARD BIOTOOLS INC. (LAB) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LAB at 35.4/100 on a composite quality score built from its SEC filings, placing it at rank #2,297 of 2,925 stocks — the bottom half of the AI-ranked universe. LAB scores in the top quartile across profitability (99.3), balance sheet strength (92.2). Areas of concern include revenue growth (5.0) and free cash flow (6.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), STANDARD BIOTOOLS INC. reports quarterly revenue of $20.1M, net income of $-26.8M, an operating margin of -126.3%. Top institutional holders of LAB by reported 13-F value include Casdin Capital, VIKING GLOBAL INVESTORS, MAK CAPITAL ONE, based on the most recent SEC filings. LAB trades on the Nasdaq exchange and files with the SEC under CIK 1162194. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LAB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for STANDARD BIOTOOLS INC. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1162194 →